Co-op Student, In Vitro Pharmacology

Zymeworks Inc.

2mo ago

Applications are closed

Internship
Full-time
Off-cycle Internship
Science
Vancouver

Requirements

Currently be enrolled in an undergraduate program in Biology, Biochemistry, Microbiology, Immunology or a related discipline
Must be available for a co-op term of at least 8-months. Successful completion of at least one relevant co-op term is preferred
Must be able to work onsite in Vancouver, BC, without relocation assistance
Skills and Abilities:
Interpersonal skills with the ability to establish and maintain effective working relationships
Organizational skills and the ability to work effectively in a high-paced, fast-changing environment
Enthusiasm for innovation and discovery
Excellent communication skills
Good computer skills particularly with Excel and PowerPoint
Basic working knowledge of antibody structure and function

Responsibilities

Support mammalian tissue culture activities of the assay group using aseptic techniques.
Ensure cell lines are properly expanded, frozen down and databases updated as required.
Assist in interrogating novel biology utilizing flow cytometry, high content imaging, MSD or other techniques.
Execute functional immunological assays such as on cell binding, reporter gene assays, ADCC, TDCC, and/or ADCP.
Adhere to Zymeworks standard procedures for generating, documenting and archiving data and maintaining an accurate, up-to-date lab notebook or electronic notebook.
Analyze data, prepare slides, and communicate results.
Work closely with other members of the assays team and conduct all activities in accordance with scientific standards, OS&H regulations and established Zymeworks policies and practices.

Zymeworks Inc.

Developing novel medicines for patients with difficult-to-treat cancers and other serious diseases.

Science & Healthcare

Industry

201-500

Employees

2003

Founded Year

Mission & Purpose

Zymeworks (NASDAQ:ZYME) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks’ second product candidate, Zanidatamab Zovodotin (ZW49), is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker-cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.